Skip to main content

Site notifications

Notice for tozinameran & famtozinameran (COMIRNATY BIVALENT BA.4/BA.5 COVID-19 VACCINE) (Pfizer Australia Pty Ltd)

Active ingredients
tozinameran & famtozinameran
Date of review outcome
Lapse date
Type
Provisional determination
Indication
Booster for active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2
Therapeutic area
Infectious diseases

Help us improve the Therapeutic Goods Administration site